Complex Regulation of Tau Phosphorylation by the Endothelin System in Brain Microvascular Endothelial Cells (BMVECs): Link to Barrier Function

Endothelin-1 (ET-1), the most potent vasoconstrictor identified to date, contributes to cerebrovascular dysfunction. ET-1 levels in postmortem brain specimens from individuals diagnosed with Alzheimer’s Disease (AD) and related dementias (ADRD) were shown to be related to cerebral hypoxia. ET-1-mediated vascular dysfunction and ensuing cognitive deficits have also been reported in experimental models of AD and ADRD. Moreover, studies also showed that ET-1 secreted from BMVECs can affect neurovascular unit integrity in an autocrine and paracrine manner. Vascular contributions to cognitive impairment and dementia (VCID) is a leading ADRD cause known to be free of neuronal tau pathology, a hallmark of AD. However, a recent study reported cytotoxic hyperphosphorylated tau (p-tau) accumulation, which fails to bind or stabilize microtubules in BMVECs in VCID. Thus, the study aimed to determine the impact of ET-1 on tau pathology, microtubule organization, and barrier function in BMVECs. Cells were stimulated with 1uM ET-1 for 24 hours in the presence/absence of ETA (BQ123; 20uM) or ETB (BQ788; 20uM) receptor antagonists. Cell lysates were assayed for an array of phosphorylation site-specific antibodies and microtubule organization/stabilization markers. ET-1 stimulation increased p-tau Thr231 but decreased p-tau Ser199, Ser262, Ser396, and Ser214 levels only in the presence of ETA or ETB antagonism. ET-1 also impaired barrier function in the presence of ETA antagonism. These novel findings suggest that 1) dysregulation of endothelial tau phosphorylation may contribute to cerebral microvascular dysfunction and 2) the ET system may be an early intervention  target to prevent hyperphosphorylated tau-mediated disruption of BMVEC barrier function.